ITRM20010356A1 - "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina. - Google Patents

"5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.

Info

Publication number
ITRM20010356A1
ITRM20010356A1 IT2001RM000356A ITRM20010356A ITRM20010356A1 IT RM20010356 A1 ITRM20010356 A1 IT RM20010356A1 IT 2001RM000356 A IT2001RM000356 A IT 2001RM000356A IT RM20010356 A ITRM20010356 A IT RM20010356A IT RM20010356 A1 ITRM20010356 A1 IT RM20010356A1
Authority
IT
Italy
Prior art keywords
sub
ligands
halogen
triptamin
serotonin receptor
Prior art date
Application number
IT2001RM000356A
Other languages
English (en)
Inventor
Cesare Maria Assunta Di
Patrizia Minetti
Giorgio Tarzia
Gilberto Spadoni
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Priority to IT2001RM000356A priority Critical patent/ITRM20010356A1/it
Publication of ITRM20010356A0 publication Critical patent/ITRM20010356A0/it
Priority to PCT/IT2002/000398 priority patent/WO2003000252A1/en
Priority to DE60230270T priority patent/DE60230270D1/de
Priority to JP2003506898A priority patent/JP4683839B2/ja
Priority to CA2455296A priority patent/CA2455296C/en
Priority to CNB02814337XA priority patent/CN100482223C/zh
Priority to KR1020037016564A priority patent/KR100885308B1/ko
Priority to BR0210538-1A priority patent/BR0210538A/pt
Priority to MXPA03011510A priority patent/MXPA03011510A/es
Priority to PL02367618A priority patent/PL367618A1/xx
Priority to CZ20033314A priority patent/CZ20033314A3/cs
Priority to ES02745793T priority patent/ES2319107T3/es
Priority to AT02745793T priority patent/ATE416767T1/de
Priority to SK38-2004A priority patent/SK287828B6/sk
Priority to US10/481,433 priority patent/US7098233B2/en
Priority to PT02745793T priority patent/PT1404317E/pt
Priority to DK02745793T priority patent/DK1404317T3/da
Priority to HU0400250A priority patent/HUP0400250A3/hu
Priority to EP02745793A priority patent/EP1404317B1/en
Priority to AU2002317482A priority patent/AU2002317482B2/en
Publication of ITRM20010356A1 publication Critical patent/ITRM20010356A1/it
Priority to HK05101226.9A priority patent/HK1068792A1/xx
Priority to CY20091100260T priority patent/CY1108879T1/el
Priority to JP2010204733A priority patent/JP2011016835A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
IT2001RM000356A 2001-06-21 2001-06-21 "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina. ITRM20010356A1 (it)

Priority Applications (23)

Application Number Priority Date Filing Date Title
IT2001RM000356A ITRM20010356A1 (it) 2001-06-21 2001-06-21 "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
AU2002317482A AU2002317482B2 (en) 2001-06-21 2002-06-17 5-halo-tryptamine derivatives used as ligands of the 5-HT6 and/or 5-HT7 serotonin receptors
CZ20033314A CZ20033314A3 (cs) 2001-06-21 2002-06-17 Použití Q@halogentryptaminových derivátů jako ligandů Q@HT@ a@nebo Q@HT@ receptorů pro serotonin
AT02745793T ATE416767T1 (de) 2001-06-21 2002-06-17 5-halo-tryptaminderivate als 5-ht6 und/oder 5-ht7 rezeptorliganden
JP2003506898A JP4683839B2 (ja) 2001-06-21 2002-06-17 ５−ｈｔ６および／または５−ｈｔ７セロトニン受容体のリガンドとして使用される５−ハロ−トリプタミン誘導体
CA2455296A CA2455296C (en) 2001-06-21 2002-06-17 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht7 serotonin receptors
CNB02814337XA CN100482223C (zh) 2001-06-21 2002-06-17 用作5-ht6和/或5-ht75-羟色胺受体的配体的5-卤代-色胺衍生物
KR1020037016564A KR100885308B1 (ko) 2001-06-21 2002-06-17 ５－ｈｔ6 및／또는 ５－ｈｔ7 세로토닌 수용체의리간드로서 사용되는 ５－할로-트립타민 유도체
BR0210538-1A BR0210538A (pt) 2001-06-21 2002-06-17 Derivados de 5-halotriptamina usados como ligantes dos receptores de serotonina 5-ht6 e/ou 5-ht7
MXPA03011510A MXPA03011510A (es) 2001-06-21 2002-06-17 Derivados de5-halo-triptamina usados como ligandos de receptores de serotonina 5-ht-6 y/o 5-ht-7.
PL02367618A PL367618A1 (en) 2001-06-21 2002-06-17 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht 7 serotonin receptors
PCT/IT2002/000398 WO2003000252A1 (en) 2001-06-21 2002-06-17 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht7 serotonin receptors
ES02745793T ES2319107T3 (es) 2001-06-21 2002-06-17 Derivados de 5-halo-triptamina usados como ligandos de los receptores de serotonina 5-ht6 y/o 5-ht7.
DE60230270T DE60230270D1 (de) 2001-06-21 2002-06-17 5-halo-tryptaminderivate als 5-ht6 und/oder 5-ht7 rezeptorliganden
SK38-2004A SK287828B6 (sk) 2001-06-21 2002-06-17 5-Halo-tryptamine derivatives used as ligands of 5-HT6 and/or 5-HT7 serotonin receptors
US10/481,433 US7098233B2 (en) 2001-06-21 2002-06-17 5-halo-tryptamine derivatives used as ligands on the 5-HT6 and/or 5-HT7 serotonin receptors
PT02745793T PT1404317E (pt) 2001-06-21 2002-06-17 Derivados de 5-halo-triptamina utilizados como ligandos dos receptores serotoninérgicos 5-ht6 e/ou 5-ht7
DK02745793T DK1404317T3 (da) 2001-06-21 2002-06-17 5-Halogentryptaminderivater til anvendelse som ligander af 5-HT6- og/eller 5-HT7-serotoninreceptorer
HU0400250A HUP0400250A3 (en) 2001-06-21 2002-06-17 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht7 serotonin receptors, their preparation and their use for preparation of pharmaceutical compositions
EP02745793A EP1404317B1 (en) 2001-06-21 2002-06-17 5-halo-tryptamine derivatives used as ligands of the 5-ht 6? and/or 5-ht 7? serotonin receptors
HK05101226.9A HK1068792A1 (en) 2001-06-21 2005-02-16 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht7 serotonin receptors
CY20091100260T CY1108879T1 (el) 2001-06-21 2009-03-06 Παραγωγα 5-αλο-τρυπταμινης που χρησιμοποιουνται ως συνδετες των σεροτονικων υποδοχεων 5-ητ6 και/ή 5-ητ7
JP2010204733A JP2011016835A (ja) 2001-06-21 2010-09-13 ５−ｈｔ６および／または５−ｈｔ７セロトニン受容体のリガンドとして使用される５−ハロ−トリプタミン誘導体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001RM000356A ITRM20010356A1 (it) 2001-06-21 2001-06-21 "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.

Publications (2)

Publication Number Publication Date
ITRM20010356A0 ITRM20010356A0 (it) 2001-06-21
ITRM20010356A1 true ITRM20010356A1 (it) 2002-12-23

Family

ID=11455609

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2001RM000356A ITRM20010356A1 (it) 2001-06-21 2001-06-21 "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.

Country Status (22)

Country Link
US (1) US7098233B2 (it)
EP (1) EP1404317B1 (it)
JP (2) JP4683839B2 (it)
KR (1) KR100885308B1 (it)
CN (1) CN100482223C (it)
AT (1) ATE416767T1 (it)
AU (1) AU2002317482B2 (it)
BR (1) BR0210538A (it)
CA (1) CA2455296C (it)
CY (1) CY1108879T1 (it)
CZ (1) CZ20033314A3 (it)
DE (1) DE60230270D1 (it)
DK (1) DK1404317T3 (it)
ES (1) ES2319107T3 (it)
HK (1) HK1068792A1 (it)
HU (1) HUP0400250A3 (it)
IT (1) ITRM20010356A1 (it)
MX (1) MXPA03011510A (it)
PL (1) PL367618A1 (it)
PT (1) PT1404317E (it)
SK (1) SK287828B6 (it)
WO (1) WO2003000252A1 (it)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4455064B2 (ja) 2002-03-27 2010-04-21 グラクソ グループ リミテッド キノリン誘導体および５−ｈｔ６リガンドとしてのその使用
EA009732B1 (ru) 2003-07-22 2008-02-28 Арена Фармасьютикалз, Инк. Диарильные и арилгетероарильные производные мочевины в качестве модуляторов 5-ht-рецептора серотонина, пригодные для профилактики и лечения связанных с ним заболеваний
US8086315B2 (en) 2004-02-12 2011-12-27 Asap Medical, Inc. Cardiac stimulation apparatus and method for the control of hypertension
JPWO2005079845A1 (ja) * 2004-02-20 2007-08-02 アステラス製薬株式会社 片頭痛予防薬
EP1852129A4 (en) * 2005-02-08 2009-07-15 Astellas Pharma Inc REMEDIES FOR IRRITATION SYNDROME
WO2007018168A1 (ja) 2005-08-08 2007-02-15 Astellas Pharma Inc. アシルグアニジン誘導体またはその塩
WO2007046112A1 (en) * 2005-10-19 2007-04-26 Suven Life Sciences Inc. Arylthioether tryptamine derivatives as functional 5-ht6 ligands
WO2007097276A1 (ja) * 2006-02-20 2007-08-30 Astellas Pharma Inc. ピロール誘導体またはその塩
EP2120950B1 (en) * 2007-03-21 2012-07-04 Glaxo Group Limited Use of quinoline derivatives in the treatment of pain
AU2008310883A1 (en) * 2007-10-09 2009-04-16 Hamann, Mark T Method to use compositions having antidepressant anxiolytic and other neurological activity and compositions of matter
WO2009074607A1 (en) 2007-12-12 2009-06-18 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
RU2648474C2 (ru) * 2011-08-05 2018-03-26 Сукампо Аг Способ лечения шизофрении
CN102816103B (zh) * 2012-08-20 2014-05-07 冉瑞琼 硫化天冬氨酸修饰的退黑素衍生物及其应用
US9008769B2 (en) 2012-12-21 2015-04-14 Backbeat Medical, Inc. Methods and systems for lowering blood pressure through reduction of ventricle filling
US9370662B2 (en) 2013-12-19 2016-06-21 Backbeat Medical, Inc. Methods and systems for controlling blood pressure by controlling atrial pressure
CN104529865B (zh) * 2014-12-12 2017-02-01 广东东阳光药业有限公司 苄胺类衍生物及其在药物上的应用
EP4119141A1 (en) 2015-06-12 2023-01-18 Axovant Sciences GmbH Nelotanserin for the prophylaxis and treatment of rem sleep behavior disorder
BR112018000728A2 (pt) 2015-07-15 2018-09-04 Axovant Sciences Gmbh resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo
US10342982B2 (en) 2015-09-11 2019-07-09 Backbeat Medical, Inc. Methods and systems for treating cardiac malfunction
US10485658B2 (en) 2016-04-22 2019-11-26 Backbeat Medical, Inc. Methods and systems for controlling blood pressure
CN108926565A (zh) * 2017-05-26 2018-12-04 中国科学院上海生命科学研究院 五羟色胺受体亚型6小分子激活剂及拮抗剂在防治阿尔茨海默症中的应用
EP3813810A4 (en) * 2018-06-21 2022-03-30 Robert John Petcavich METHODS OF INDUCING DENDRITICAL AND SYNAPTIC GENESIS IN CHRONIC NEURODEGENERATIVE DISEASES
KR20230012501A (ko) 2020-05-19 2023-01-26 사이빈 아이알엘 리미티드 중수소화된 트립타민 유도체 및 사용 방법
WO2022061196A1 (en) * 2020-09-18 2022-03-24 Mydecine Innovations Group Inc. Novel formulations of psilocybin and psilocin compounds as serotonin agonists in combination with 3,4 methylenedioxymethamphetamine (mdma)
WO2023018480A1 (en) * 2021-08-09 2023-02-16 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Selective psychedelic compounds
WO2023129956A2 (en) * 2021-12-30 2023-07-06 ATAI Life Sciences AG Dimethyltryptamine analogues as nitric oxide delivery drugs
CN114573578B (zh) * 2022-02-16 2023-11-17 烟台宁远药业有限公司 一种烷基取代氮杂吲哚的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2825734A (en) * 1955-04-11 1958-03-04 Upjohn Co Reduction of carbonylic radicals in indolyl-3 compounds
GB966562A (en) * 1961-04-06 1964-08-12 Parke Davis & Co Amine compounds and means of producing the same
FR2315277A1 (fr) * 1975-06-25 1977-01-21 Anvar Nouveaux derives pentacycliques, leur preparation et les compositions qui les contiennent
US4428877A (en) * 1978-07-12 1984-01-31 Richter Gedeon Vegyeszeti Gyar Rt. Cis-10-bromo-E-homoeburnanes
GB8531612D0 (en) * 1985-12-23 1986-02-05 Beecham Wuelfing Gmbh & Co Kg Compounds
US5300645A (en) * 1993-04-14 1994-04-05 Eli Lilly And Company Tetrahydro-pyrido-indole
FR2712591B1 (fr) * 1993-11-19 1996-02-09 Pf Medicament Nouvelles arylpipérazines dérivées d'indole, leur préparation et leur utilisation thérapeutique.
US5688807A (en) * 1994-03-11 1997-11-18 Eli Lilly And Company Method for treating 5HT2B receptor related conditions
US5504101A (en) * 1994-05-06 1996-04-02 Allelix Biopharmaceuticals, Inc. 5-HT-1D receptor ligands
DE69733427T2 (de) 1996-06-28 2006-04-27 Meiji Seika Kaisha Ltd. Tetrahydrobezindol derivate
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
US6251893B1 (en) * 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
AU767009B2 (en) * 1998-12-11 2003-10-30 Virginia Commonwealth University Selective 5-HT6 receptor ligands
US6403808B1 (en) * 1999-12-10 2002-06-11 Virginia Commonwealth University Selective 5-HT6 receptor ligands
ATE375990T1 (de) 1999-04-21 2007-11-15 Nps Allelix Corp Piperidin-indol derivate mit 5-ht6 affinität
ATE268330T1 (de) 1999-08-12 2004-06-15 Nps Allelix Corp Azaidole mit serotonin rezeptor affinität
WO2004041781A1 (en) * 2002-11-07 2004-05-21 Suven Life Sciences Limited Preparation of 3-aminoalkyl-substituted indole derivatives from phenylhydrazines and aminoketones

Also Published As

Publication number Publication date
ES2319107T3 (es) 2009-05-04
CA2455296C (en) 2010-08-17
EP1404317A1 (en) 2004-04-07
JP2011016835A (ja) 2011-01-27
KR20040032113A (ko) 2004-04-14
AU2002317482B2 (en) 2007-08-16
DK1404317T3 (da) 2009-02-23
EP1404317B1 (en) 2008-12-10
BR0210538A (pt) 2004-06-22
ATE416767T1 (de) 2008-12-15
US20040235899A1 (en) 2004-11-25
PL367618A1 (en) 2005-03-07
HUP0400250A3 (en) 2008-03-28
CA2455296A1 (en) 2003-01-03
WO2003000252A1 (en) 2003-01-03
DE60230270D1 (de) 2009-01-22
JP2004534816A (ja) 2004-11-18
MXPA03011510A (es) 2004-03-18
HUP0400250A2 (hu) 2004-08-30
SK287828B6 (sk) 2011-11-04
US7098233B2 (en) 2006-08-29
CN1535146A (zh) 2004-10-06
KR100885308B1 (ko) 2009-02-24
CZ20033314A3 (cs) 2004-08-18
CN100482223C (zh) 2009-04-29
JP4683839B2 (ja) 2011-05-18
ITRM20010356A0 (it) 2001-06-21
CY1108879T1 (el) 2014-07-02
SK382004A3 (en) 2004-05-04
HK1068792A1 (en) 2005-05-06
PT1404317E (pt) 2009-02-23

Similar Documents

Publication Publication Date Title
ITRM20010356A1 (it) "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
BR0210929A (pt) Derivados de indol com afinidade para o receptor 5-ht6
DK2314582T3 (da) Heterocykliske forbindelser som antivirusmidler
EA200200360A1 (ru) Производные пурина
EA200201179A1 (ru) Производные 2-аминокарбонил-9h-пурина
AR021055A1 (es) Derivados de pirazolopiridina
HK1070054A1 (en) Arylsulfonyl derivatives with5-ht6 receptor affinity
BRPI0209216B8 (pt) derivados de quinolina e de quinazolina, composições farmacêuticas compreendendo os mesmos e seus usos
EA200300619A1 (ru) Серотонинергические средства
BR0215151A (pt) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
SE9903997D0 (sv) New compounds
DK1643984T3 (da) Anvendelse af parthenolidderivater som antileukæmiske og cytotoksske midler
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
HUP0104852A2 (hu) Oktahidro-pirido-pirazil-származékok és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
PT1204658E (pt) Agonistas benzofurilpiperazina de serotonina
ES2175405T3 (es) Derivados de adenosina.
SE0302572D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
DK0516350T3 (da) 2-hydroxy-2-phenylethylamin-derivater som beta-3-adrenoceptoragonister
ATE274515T1 (de) Pyrazolopyridinderivate
DK0982305T3 (da) Indan-1-ol-derivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende derivaterne
ATE285771T1 (de) Diaminotrifluoromethylpyrimidinderivate enthaltende antikrebs-zusammensetzung
SE0301371D0 (sv) New Compounds
EA200101180A1 (ru) Производные тио-оксиндола
PE20030338A1 (es) Utilizacion de derivados de sistemas de indan-1-ol-sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad